<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05125692</url>
  </required_header>
  <id_info>
    <org_study_id>osama Istmocele</org_study_id>
    <nct_id>NCT05125692</nct_id>
  </id_info>
  <brief_title>Vaginal Repair of Post Cesarean Istmocele</brief_title>
  <acronym>OWarda</acronym>
  <official_title>Vaginal Repair of Symptomatic Postcesarean Isthmocele: Evaluating A Simple Novel Technique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      20 WOMEN WITH SYMPTOMATIC POSTCESAREAN ISTHMOCELE (NICHE) WILL BE RECRUITED EVALUATED AND&#xD;
      SUBJECTED TO A VAGINAL REPAIR OF THE DEFECT, RESULTS WILL BE ANALYZED.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      METHODS:&#xD;
&#xD;
        -  Subjects: women in childbearing period with abnormal uterine bleeding or infertility&#xD;
           attributed to post cesarean isthmocele (sample size to be calculated)&#xD;
&#xD;
        -  Preoperative evaluation: transvaginal ultrasound to exclude any other uterine or adnexal&#xD;
           pathology, and to measure:&#xD;
&#xD;
             1. Distance from the external cervical os to the lower end of the isthmocele (A)&#xD;
&#xD;
             2. Distance from the external cervical os to the upper end of the isthmocele(B)&#xD;
&#xD;
             3. Length of the isthmocele (B-A)&#xD;
&#xD;
             4. Residual myometrial thickness (the least) of the isthmocele.&#xD;
&#xD;
        -  Routine preoperative workup.&#xD;
&#xD;
        -  The technique:&#xD;
&#xD;
             -  Postmenstrual&#xD;
&#xD;
             -  Spinal anesthesia&#xD;
&#xD;
             -  Sterilization of the perineum and vagina&#xD;
&#xD;
             -  Cervical dilation up to 8mm using Hegar's dilators&#xD;
&#xD;
             -  Marking the previously measured points A &amp; B&#xD;
&#xD;
             -  Making 2 transverse incisions, one 5mm below A and the other 5 mm above B.&#xD;
&#xD;
             -  The rectangular area between the 2 incisions is excised while the Hegar's dilator&#xD;
                number 8 in in situ.&#xD;
&#xD;
             -  Hemostasis is performed using diathermy.&#xD;
&#xD;
             -  The upper and lower edges of the incision are approximated using number 2/0 vicryl&#xD;
                on cutting needle taking 3 to 4 interrupted sutures&#xD;
&#xD;
        -  The patients with uneventful postoperative course are discharged from hospital after 8&#xD;
           hours with doxycycline 100 mg bid for 5 days.&#xD;
&#xD;
        -  Sexual intercourse is avoided for 4 weeks postoperative&#xD;
&#xD;
        -  postoperative transvaginal ultrasound follow up; at 1 month postoperative.&#xD;
&#xD;
        -  Data will be statistically analyzed and results will be tabulated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>WOMEN IN CHILDBEARING PERIOD WITH SYMPTOMATIC POSTCESAREAN ISTHMOCELE</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>myometrial thickness in supracervical area</measure>
    <time_frame>at 1 month postoperative</time_frame>
    <description>the myometrial thickness in the supracervical region is measured by transvaginal ultrasound postoperatively</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Gynecologic Disease</condition>
  <arm_group>
    <arm_group_label>women with symptomatic post cesarean Istmocele</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>vaginal surgical repair of post cesarean symptomatic isthmocele using conventional low cost surgical techniques</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>vaginal surgical repair of isthmocele</intervention_name>
    <description>after preoperative identification of the borders of the isthmocele using transvaginal ultrasound measurements, the isthmocele is repaired via vaginal approach</description>
    <arm_group_label>women with symptomatic post cesarean Istmocele</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  women diagnosed with symptomatic post cesarean isthmocele.&#xD;
&#xD;
          -  should present with abnormal uterine bleeding .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  presence of any other uterine pathology,&#xD;
&#xD;
          -  presence of adnexal pathology,&#xD;
&#xD;
          -  presence of malignancies,&#xD;
&#xD;
          -  presence of pregnancy,&#xD;
&#xD;
          -  presence of infection in the lower genital tract ,&#xD;
&#xD;
          -  general cause of bleeding&#xD;
&#xD;
          -  women not accepting the procedure,&#xD;
&#xD;
          -  women not consented&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>osama M Warda, MD</last_name>
    <phone>01066153212</phone>
    <phone_ext>+20</phone_ext>
    <email>osamawarda@mans.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mansoura University Hospitals</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlya Governorate</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>osama m warda, MD</last_name>
      <phone>01066153212</phone>
      <phone_ext>+20</phone_ext>
      <email>osamawarda@mans.edu.eg</email>
    </contact>
    <investigator>
      <last_name>osama m warda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 6, 2021</last_update_submitted>
  <last_update_submitted_qc>November 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

